TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Immunological safety - donor-derived cell-free DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression levels of Interleukin 37
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of AE05ML
Endpoint domain: Adverse events/effects
Primary endpoint: Performance of AE05ML
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients choosing prosthesis or epithesis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difference in capability rate of vaginal and/or anal penetration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: NIR fluorescence of the meniscus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average delay in days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient satisfaction Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of Exit Interview
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of pancreatic exocrine insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Contraceptive discontinuation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Success rate of coagulation and disconnection of target blood vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sleep Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Pelvic Pain Score on Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality due to Severe COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: percent of collagen formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of wound size measurement methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin morphological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin molecular signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients receiving full multimodal treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PDUS signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood flow in fetal veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: blood flow in fetal arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in EEG Oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Emotion Recognition Task score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Reading the Mind in the Eyes Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: number of ambulatory care after total mastectomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean change in WOMAC composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentration of IS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dialysate concentration of IS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine concentration of IS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate Cancer Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain relief (response rate)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Epworth sleepiness Scale (ESS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Contrast-to-noise ratio between thalamic nuclei
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pearson correlation between thalamocortical brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microstate duration in EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of PET-MR imaging indicators in AD progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Role of degeneration and vascular factors in cognition development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Berg Scale Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with any solicited local injection site Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with any solicited systemic Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with any related Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Non-substance use behavior
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Consequences of addictive behaviors
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Early metabolic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HsCRP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of initial HRCT interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success-rate of resection of the marked lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in microbial colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Element adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: differences in immune cell subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cognitive function testing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Brain MRI structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sciatica bothersomeness Index for sciatica
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Short Form Health Survey (SF-36) questionnaire for quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Target engagement attributable to G3P-01
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of G3P-01
Endpoint domain: Adverse events/effects
Primary endpoint: Change in composite score of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reduction of headache frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of headache severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of headache duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of headache impact
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in PCR% - Plaque Control Record (percentage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in microbiological loads of clear aligners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with post-hepatectomy liver failure (PHLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Total Intraoperative opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of Sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to onset of Motor Blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to first analgesic request post operatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Consolidation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weiss Functional Impairment Rating Scale - WFIRS
Endpoint domain: Life impact
Endpoint subdomain: Functional functioning
Primary endpoint: General Anxiety Disorder (GAD) 7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Infusion Related Reactions (IRRs) and Other AEs of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Permanently Discontinuing Study Treatment Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-related effect on NASH status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Ratings of Painful and Painless Sensory Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histomorphometric results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of 60-Day Patient Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients who enroll in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients who complete the PRISM intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Irritation Potential
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic and planning accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of Grade 3 Adverse Reactions (ARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequencies of Serious Adverse Reactions (SARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequencies and intensities of solicited local Adverse Reactions (ARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequencies, intensities, and duration of solicited systemic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence and intensities of unsolicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in gut microbiota function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ophthalmological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of bone consolidation period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Providers' Rates of Placing or Treatment Planning Sealants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Resolution of nasal congestion symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Pain Catastrophizing Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Platelet count response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Satisfaction of pelvic muscle training (UDI-6)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction of pelvic muscle training (ICIQ-SF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction of pelvic muscle training (IIQ-7)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction of pelvic muscle training (POPDI-6)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction of pelvic muscle training (PISQ-IR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of fluid recruited via endothelial wall vs lymph
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day abstinence from combustible tobacco
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day abstinence from combustible tobacco
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Psychological Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Albumin escape rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Correlation between vaginal sample DNA sequencing and VVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of clinical success in pulpotomies and indirect pulp caps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of radiographic success in pulpotomies and indirect pulp caps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants suffering from CVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of CVS symptoms-attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbon monoxide-verified smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and level of adverse events (AE) and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of PVAs
Endpoint domain: Adverse events/effects
Primary endpoint: Chinese Handwriting Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chinese character recognition Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chinese Handwriting Evaluation Form (preschool version)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Chinese Handwriting Evaluation Form (School-aged version)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Battery of Chinese Basic Literacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients with PSA levels rising of 2ng/ml or above
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Myocardial Microvascular Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dual Task assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallow assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Chewing Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of post-operative acute rhinosinusitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall Health Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acceptability and adherence to exercise program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fall Efficacy Scale - International (FES-I)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients with KIT D816V mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with no coronal or peri-radicular pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Retention Percentage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Expression of molecular/cellular/genomic targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Appointment Keeping Frequency
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Client Satisfaction Questionnaire (CSQ-3)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The Clinical Impairment Assessment Questionnaire (CIA)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Tiffeneau ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with Detected Neuro-Ophthalmological Manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants with Detected Cardiac and Aortic Involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Immune Cell Phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Shortness of breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental area under the curve of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time below 3.9 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of total and free triiodothyronine (T3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum levels of total and free L-thyroxine (T4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum levels of total and free thyroid stimulating hormone (TSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum levels of total and free reverse T3 (rT3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: QRISK-3 Risk Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-Hour Ambulatory Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patency of arteriovenous fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Arteriovenous fistula diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cumulative Incidence of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: MDTM concordance with approved guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Post-provocation Urticaria Activity Score (UASprovo)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Tecar therapy success in treating PDPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of tumors exhibiting disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlation coefficient between mPAP and right heart catheterization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Worst Breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Artery wall stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High-sensitivity C-reactive protein (HS-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to detection of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants achieving none or mild on the Facial Wrinkle Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flavor liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Well-being Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severity of osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference in SDS-PFD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Functioning: Role (GFR) Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Global Functioning: Social (GFS) Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Premenstrual Symptoms Screening Tool (PSST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of distinct subgroups of HFpEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improve understanding of the causes of HFpEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improve risk stratification of HFpEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Equalization of breast cup size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression associated with intestinal barrier function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Delayed Elimination of Methotrexate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Severe Delayed Elimination of Methotrexate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: HER2 therapy disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: CTCs disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Haemoglobin decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient's preference for treatment regimen
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances